Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration

{"PURPOSE:":[0],"Microhematuria":[1],"may":[2,246],"be":[3],"a":[4,31,69,136,166],"sign":[5],"of":[6,12,27,34,42,51,77,120,132,176,179,191,203,213],"underlying":[7],"genitourinary":[8],"pathology,":[9],"but":[10],"diagnoses":[11],"bladder":[13,28,71,113,138,168,181,216],"cancer":[14,29,72,139,169,182,217],"are":[15],"rare":[16],"among":[17,231],"those":[18],"who":[19],"complete":[20],"evaluations.":[21],"This":[22],"study":[23],"determines":[24],"the":[25,39,48,56,117,128,192],"incidence":[26],"in":[30],"large":[32],"cohort":[33],"patients":[35,125,204],"with":[36,80,96,126,165,221],"microhematuria,":[37,127],"assesses":[38],"diagnostic":[40,244],"potential":[41],"current":[43,193],"guideline":[44],"recommendations,":[45],"and":[46,111,135,147,160,198],"characterizes":[47],"relative":[49,239],"risks":[50],"clinicodemographic":[52,109,224],"factors":[53],"to":[54,91,104],"inform":[55],"need":[57],"for":[58,116,173,200,250],"microhematuria":[59],"evaluation.":[60,251],"MATERIALS":[61],"AND":[62],"METHODS:":[63],"microhematuria.":[64,81],"The":[65,99],"main":[66],"outcome":[67],"was":[68,102,185],"new":[70,137,167],"diagnosis":[73,140,170],"within":[74],"2":[75],"years":[76],"index":[78],"urinalysis":[79],"Patients":[82],"were":[83,141,163],"stratified":[84],"by":[85,208],"American":[86],"Urologic":[87],"Association":[88],"risk":[89,94,119,175,218],"categories":[90],"compare":[92],"guideline-based":[93],"classification":[95],"model-based":[97],"estimation.":[98],"Fine-Gray":[100],"method":[101],"used":[103],"estimate":[105],"adjusted":[106,172],"associations":[107],"between":[108],"characteristics":[110],"incident":[112],"cancer,":[114],"accounting":[115],"competing":[118,174],"death.":[121,177],"RESULTS:":[122],"Among":[123],"267,133":[124],"two-year":[129],"cumulative":[130],"incidences":[131],"cystoscopy":[133],"completion":[134],"11.9%":[142],"(95%":[143,149],"CI":[144,150],"11.7,":[145],"12.0)":[146],"1.5%":[148],"1.4,":[151],"1.5),":[152],"respectively.":[153],"Older":[154],"age,":[155],"male":[156],"sex,":[157],"smoking":[158],"history,":[159],"≥25":[161],"RBC/hpf":[162],"associated":[164],"when":[171],"Performance":[178],"our":[180],"prediction":[183],"model":[184],"better":[186],"(ROC":[187],"AUC=0.63)":[188],"than":[189],"that":[190,237],"AUA":[194,209],"guidelines":[195],"(AUC=0.52,":[196],"p<0.001)":[197],"allowed":[199],"further":[201],"risk-estimation":[202],"designated":[205],"\\"high":[206,232],"risk\\"":[207,233],"criteria.":[210],"CONCLUSIONS:":[211],"Estimation":[212],"patient-level":[214],"microhematuria-related":[215],"is":[219],"possible":[220],"readily":[222],"available":[223],"factors.":[225],"Current":[226],"approaches":[227,236],"lack":[228],"nuance,":[229],"particularly":[230],"patients.":[234],"Precision":[235],"use":[238],"risk-factor":[240],"weights":[241],"and/or":[242],"novel":[243],"tools":[245],"improve":[247],"individualized":[248],"decision-making":[249]}

Authors

Institutions

Publication Details

Journal
The Journal of Urology
Published
2026-09-16
DOI
https://doi.org/10.1097/ju.0000000000005312
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration

Vincent D'Andrea, Ekaterina Shishova, Richard S. Matulewicz, Danielle Candelieri-Surette et al.
The Journal of Urology
Bladder and Urothelial Cancer Treatments
article

Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration

Vincent D'Andrea, Ekaterina Shishova, Richard S. Matulewicz, Danielle Candelieri-Surette, Scott E Sherman, Patrick R. Alba, Samuel Gold, Bernard H. Bochner, Fady Baky, Danil V. Makarov, Andrew Nicholson, Amy L. Voorhees, Julie A. Lynch
article en

Abstract

PURPOSE: Microhematuria may be a sign of underlying genitourinary pathology, but diagnoses of bladder cancer are rare among those who complete evaluations. This study determines the incidence of bladder cancer in a large cohort of patients with microhematuria, assesses the diagnostic potential of current guideline recommendations, and characterizes the relative risks of clinicodemographic factors to inform the need for microhematuria evaluation. MATERIALS AND METHODS: microhematuria. The main outcome was a new bladder cancer diagnosis within 2 years of index urinalysis with microhematuria. Patients were stratified by American Urologic Association risk categories to compare guideline-based risk classification with model-based estimation. The Fine-Gray method was used to estimate adjusted associations between clinicodemographic characteristics and incident bladder cancer, accounting for the competing risk of death. RESULTS: Among 267,133 patients with microhematuria, the two-year cumulative incidences of cystoscopy completion and a new bladder cancer diagnosis were 11.9% (95% CI 11.7, 12.0) and 1.5% (95% CI 1.4, 1.5), respectively. Older age, male sex, smoking history, and ≥25 RBC/hpf were associated with a new bladder cancer diagnosis when adjusted for competing risk of death. Performance of our bladder cancer prediction model was better (ROC AUC=0.63) than that of the current AUA guidelines (AUC=0.52, p<0.001) and allowed for further risk-estimation of patients designated "high risk" by AUA criteria. CONCLUSIONS: Estimation of patient-level microhematuria-related bladder cancer risk is possible with readily available clinicodemographic factors. Current approaches lack nuance, particularly among "high risk" patients. Precision approaches that use relative risk-factor weights and/or novel diagnostic tools may improve individualized decision-making for evaluation.

The Journal of Urology
Memorial Sloan Kettering Cancer Center (US), University of Utah (US), VA NY Harbor Healthcare System (US), NYU Langone Health (US), VA Salt Lake City Healthcare System (US)
Good health and well-being
Openalex Percentile: Top 9%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.